Table 1. Patient characteristics.
| Ghent cohort (N = 187) | RIS Cohort (N = 138) | Overall (N = 325) | African (N = 34) | Caucasian (N = 291) | ||
| Age at diagnosis, median years (IQR) | 34 (28–40) | 25 (22–30) | 29 (24–37) | 33 (26–39) | 31 (24–36) | |
| Follow-up time, median years (IQR) | 8 (6–11) | 22 (20–25) | 15 (7–22) | 8 (6–11) | 15 (8–23) | |
| Sex, N (%) | Female | 45 (24,1) | 48 (34,5) | 93 (28,4) | 23 (67,7) | 70 (24,1) |
| Male | 142 (75,9) | 90 (65,5) | 232 (71,6) | 11 (32,3) | 221 (75,9) | |
| Ethnicity, N (%) | African | 34 (18,2) | 0 (0) | 34 (10,5) | ||
| Caucasian | 153 (81,2) | 138 (100) | 291 (89,5) | |||
| Disease progression (N, %) | LTNP - Elite controller | 6 (3,2) | 42 (30,4) | 48 (14,8) | 2 (5,9) | 46 (15,8) |
| LTNP - Viremic controller | 16 (8,6) | 47 (34,1) | 63 (19,4) | 7 (20,6) | 56 (19,2) | |
| LTNP - Non controller | 17 (9,1) | 49 (35,5) | 66 (20,3) | 4 (11,8) | 62 (21,3) | |
| Normal progressor | 113 (60,4) | 0 (0,0) | 113 (34,8) | 19 (55,9) | 94 (32,3) | |
| Rapid progressor | 35 (18,7) | 0 (0,0) | 35 (10,8) | 2 (5,9) | 33 (11,3) | |
| Current ART, N (%) | Yes | 87 (46,4) | 18 (12,9) | 105 (32,3) | 13 (38,2) | 92 (31,6) |
| No | 100 (53,6) | 120 (87,1) | 220 (67,7) | 21 (61,8) | 199 (68,4) |
Overview of the patient characteristics, divided for Ghent and RIS cohort and per ethnicity (Africans, Caucasians). The number of patients per subcategory is presented for sex, ethnicity, disease progression groups and current antiretroviral treatment.
IQR = interquartile range; N = number; LTNP = long-term non-progressor; ART = antiretroviral treatment.